Abstract
A set of mouse monoclonal antibodies against the c-myc oncogene product, a 62,000 dalton nuclear binding protein involved in cell cycle control, has been constructed by immunisation with synthetic peptide fragments. One such antibody, CT14, was radiolabelled with /sup 131/I and administered to 20 patients with different malignant diseases. Good tumour localisation was observed in 12 out of 14 patients with primary bronchial carcinoma but not in patients with pulmonary metastases from primary tumours elsewhere. Successfully localised tumours were all 3 cm or more in diameter. Monoclonal antibodies against oncogene products may provide novel selective tools for the diagnosis and therapy of cancer.
Citation Formats
Chan, S Y.T., Evan, G I, Ritson, A, Watson, J, Wraight, P, and Sikora, K.
Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product.
United Kingdom: N. p.,
1986.
Web.
Chan, S Y.T., Evan, G I, Ritson, A, Watson, J, Wraight, P, & Sikora, K.
Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product.
United Kingdom.
Chan, S Y.T., Evan, G I, Ritson, A, Watson, J, Wraight, P, and Sikora, K.
1986.
"Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product."
United Kingdom.
@misc{etde_5724570,
title = {Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product}
author = {Chan, S Y.T., Evan, G I, Ritson, A, Watson, J, Wraight, P, and Sikora, K}
abstractNote = {A set of mouse monoclonal antibodies against the c-myc oncogene product, a 62,000 dalton nuclear binding protein involved in cell cycle control, has been constructed by immunisation with synthetic peptide fragments. One such antibody, CT14, was radiolabelled with /sup 131/I and administered to 20 patients with different malignant diseases. Good tumour localisation was observed in 12 out of 14 patients with primary bronchial carcinoma but not in patients with pulmonary metastases from primary tumours elsewhere. Successfully localised tumours were all 3 cm or more in diameter. Monoclonal antibodies against oncogene products may provide novel selective tools for the diagnosis and therapy of cancer.}
journal = []
volume = {54:5}
journal type = {AC}
place = {United Kingdom}
year = {1986}
month = {Nov}
}
title = {Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product}
author = {Chan, S Y.T., Evan, G I, Ritson, A, Watson, J, Wraight, P, and Sikora, K}
abstractNote = {A set of mouse monoclonal antibodies against the c-myc oncogene product, a 62,000 dalton nuclear binding protein involved in cell cycle control, has been constructed by immunisation with synthetic peptide fragments. One such antibody, CT14, was radiolabelled with /sup 131/I and administered to 20 patients with different malignant diseases. Good tumour localisation was observed in 12 out of 14 patients with primary bronchial carcinoma but not in patients with pulmonary metastases from primary tumours elsewhere. Successfully localised tumours were all 3 cm or more in diameter. Monoclonal antibodies against oncogene products may provide novel selective tools for the diagnosis and therapy of cancer.}
journal = []
volume = {54:5}
journal type = {AC}
place = {United Kingdom}
year = {1986}
month = {Nov}
}